In this second part of a video series, Managed Healthcare Executive caught up with CareOregon CEO Eric C. Hunter, who voiced concern about the consequences of rising anti-DEI views and potential federal funding cuts.
As political debates continue and grow around diversity, equity and inclusion (DEI) efforts, as well as social determinants of health (SDOH) programs, CareOregon CEO Eric C. Hunter is preparing for what could be a significant threat to the organization’s mission of equitable care.
In a conversation with Managed Healthcare Executive, Hunter voiced concern about the consequences of rising anti-DEI views and potential federal funding cuts.
“I do see that as a strong possibility,” said Hunter, referring to the chilling effect that prohibitions on DEI efforts could have on programs that serve underserved populations.
He expressed his anger that criticism often targets the acronym itself rather than the values behind it.
“Are you against diversity? Are you against equity? Are you against inclusion? Tell me what’s wrong with any of those things,” he asked.
Hunter warned that when policymakers dismiss DEI efforts, the consequences go far beyond politics.
“It really is impactful on human beings,” he said. “And that’s what I find most disturbing.”
He added that he doesn’t believe in hate or discrimination as a factor “in providing basic needs or healthcare, which I believe is a human right.”
CareOregon is proactively preparing for changes, both at the organizational and state level, Hunter said.
Internally, the team is prioritizing programs, improving efficiency and developing contingency plans to quickly respond to shifts in funding or demographics.
At the state level, Oregon is pushing back against federal efforts that threaten equity and access, with strong support from the governor and attorney general.
While Hunter acknowledges the importance of maintaining a strong partnership with the federal government, particularly agencies like CMS and CMMI, he remains firm in his commitment to CareOregon’s 550,000 members.
“We can’t and won’t ever abandon our membership or our communities for political whim or just for scoring points,” he said.
As federal budget negotiations move forward, Hunter and his team are bracing for tough decisions but remain focused on their mission: ensuring that every Oregonian has access to quality healthcare, regardless of zip code, immigration status or background.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Report: Cyberattacks Have Impacted Patient Care, Nearly 20% of Healthcare Leaders Say
June 5th 2025Although 52% of healthcare leaders believe a fatal cyber-related patient incident will happen within the next five years, cybersecurity was not ranked as a top business challenge, according to the results of Omega Systems’ 2025 Healthcare IT Landscape Report.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Kathryn Boger, Ph.D. | 2025 MHE Emerging Leaders in Healthcare
June 5th 2025Co-founder and chief clinical officer, InStride Health. InStride Health provides evidence-based care for children, teens and young adults with anxiety and obsessive-compulsive disorder (OCD) and their families.
Read More
FDA Approved Bayer’s Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
June 5th 2025The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation therapy (ADT), reduced the risk of radiographic progression or death by 46% compared to ADT with placebo.
Read More